In 1991, Prof Dr Désiré Collen and colleagues at the Katholieke Universiteit Leuven spun out Thromb-X nv. The Company's initial focus was in the cardio-vascular space. Collen, whose laboratory was the first to produce t-PA for clinical use was using part of the t-PA royalties received from Genentech to finance further developments. Thromb-X was looking at staphylokinase as it was thought to have efficacy similar to t-PA at a lower cost of goods. Later on, microplasmin (later ocriplasmin) was also looked at as a direct-acting thrombolytic. For the most part, and till 2006, the work has been financed with royalties from t-PA.